Selective modulation of activated protein C activities by a nonactive site-targeting nanobody library

Activated protein C (APC) is a pleiotropic coagulation protease with anticoagulant, antiinflammatory, and cytoprotective activities. Selective modulation of these APC activities contributes to our understanding of the regulation of these physiological mechanisms and permits the development of therapeutics for the pathologies associated with these pathways. An antibody library targeting the nonactive site of APC was generated using llama antibodies (nanobodies). Twenty-one nanobodies were identified that selectively recognize APC compared with the protein C zymogen. Overall, 3 clusters of nanobodies were identified based on the competition for APC in biolayer interferometry studies. APC functional assays for anticoagulant activity, histone H3 cleavage, and protease-activated receptor 1 (PAR1) cleavage were used to understand their diversity. These functional assays revealed 13 novel nanobody-induced APC activity profiles via the selective modulation of APC pleiotropic activities, with the potential to regulate specific mechanisms for therapeutic purposes. Within these, 3 nanobodies (LP2, LP8, and LP17) inhibited all 3 APC functions. Four nanobodies (LP1, LP5, LP16, and LP20) inhibited only 2 of the 3 functions. Monofunction inhibition specific to APC anticoagulation activity was observed only by 2 nanobodies (LP9 and LP11). LP11 was also found to shift the ratio of APC cleavage of PAR1 at R46 relative to R41, which results in APC-mediated biased PAR1 signaling and APC cytoprotective effects. Thus, LP11 has an activity profile that could potentially promote hemostasis and cytoprotection in bleedings associated with hemophilia or coagulopathy by selectively modulating APC anticoagulation and PAR1 cleavage profile.

Automated summary

Activated protein C (APC) is a multifunctional coagulation protease with anticoagulant, antiinflammatory, and cytoprotective activities. Through selective modulation of APC activities, therapeutics can be developed for pathologies associated with these mechanisms. Identification of nanobodies that selectively recognize APC has provided insights into the diversity of APC functions and their potential therapeutic applications. LP11, in particular, has been found to selectively modulate APC anticoagulation and PAR1 cleavage, suggesting its potential in promoting hemostasis and cytoprotection in bleeding disorders.